期刊论文详细信息
Radiation Oncology
Pretreatment carcinoembryonic antigen level is a risk factor for para-aortic lymph node recurrence in addition to squamous cell carcinoma antigen following definitive concurrent chemoradiotherapy for squamous cell carcinoma of the uterine cervix
Chang-Yu Wang4  Hsuan-Chih Hsu1  Hui-Chun Chen4  Hung-Chun Fu5  Yu-Che Ou5  Ching-Chou Tsai5  Chin-Wen Tseng6  Li-Min Sun3  Chong-Jong Wang4  Hao Lin5  Chan-Chao Chanchien5  Yu-Jie Huang4  Eng-Yen Huang2 
[1] School of Medicine, Chang Gung University College of Medicine, Taoyuan, Taiwan;School of Traditional Chinese Medicine, Chang Gung University College of Medicine, Taoyuan, Taiwan;Department of Radiation Oncology, Zuoying Armed Forces General Hospital, Kaohsiung, Taiwan;Department of Radiation Oncology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan;Department of Gynecologic Oncology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan;Department of Gynecologic Oncology, Chia-Yi Chang Gung Memorial Hospital, Chia-Yi, Taiwan
关键词: radiotherapy;    SCC-Ag;    uterine cervix;    squamous cell carcinoma;    para-aortic lymph node;    carcinoembryonic antigen;   
Others  :  1160903
DOI  :  10.1186/1748-717X-7-13
 received in 2011-07-23, accepted in 2012-01-30,  发布年份 2012
PDF
【 摘 要 】

Background

To identify pretreatment carcinoembryonic antigen (CEA) levels as a risk factor for para-aortic lymph node (PALN) recurrence following concurrent chemoradiotherapy (CCRT) for cervical cancer.

Methods

From March 1995 to January 2008, 188 patients with squamous cell carcinoma (SCC) of the uterine cervix were analyzed retrospectively. No patient received PALN irradiation as the initial treatment. CEA and squamous cell carcinoma antigen (SCC-Ag) were measured before and after radiotherapy. PALN recurrence was detected by computer tomography (CT) scans. We analyzed the actuarial rates of PALN recurrence by using Kaplan-Meier curves. Multivariate analyses were carried out with Cox regression models. We stratified the risk groups based on the hazard ratios (HR).

Results

Both pretreatment CEA levels ≥ 10 ng/mL and SCC-Ag levels < 10 ng/mL (p < 0.001, HR = 8.838), SCC-Ag levels ≥ 40 ng/mL (p < 0.001, HR = 12.551), and SCC-Ag levels of 10-40 ng/mL (p < 0.001, HR = 4.2464) were significant factors for PALN recurrence. The corresponding 5-year PALN recurrence rates were 51.5%, 84.8%, and 27.5%, respectively. The 5-year PALN recurrence rate for patients with both low (< 10 ng/mL) SCC and CEA was only 9.6%. CEA levels ≥ 10 ng/mL or SCC-Ag levels ≥ 10 ng/mL at PALN recurrence were associated with overall survival after an isolated PALN recurrence. Pretreatment CEA levels ≥ 10 ng/mL were also associated with survival after an isolated PALN recurrence.

Conclusions

Pretreatment CEA ≥ 10 ng/mL is an additional risk factor of PALN relapse following definitive CCRT for SCC of the uterine cervix in patients with pretreatment SCC-Ag levels < 10 ng/mL. More comprehensive examinations before CCRT and intensive follow-up schedules are suggested for early detection and salvage in patients with SCC-Ag or CEA levels ≥ 10 ng/mL.

【 授权许可】

   
2012 Huang et al; licensee BioMed Central Ltd.

【 预 览 】
附件列表
Files Size Format View
20150411083610376.pdf 413KB PDF download
Figure 3. 29KB Image download
Figure 2. 21KB Image download
Figure 1. 21KB Image download
【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】
  • [1]Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, Rotman M, Gershenson DM, Mutch DG: Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. New Engl J Med 1999, 340(15):1137-1143.
  • [2]Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, Clarke-Pearson DL, Insalaco S: Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999, 340(15):1144-1153.
  • [3]Huang EY, Wang CJ, Chen HC, Fang FM, Huang YJ, Wang CY, Hsu H: Multivariate analysis of para-aortic lymph node recurrence after definitive radiotherapy for stage IB-IVA squamous cell carcinoma of uterine cervix. Int J Radiat Oncol Biol Phys 2008, 72(3):834-842.
  • [4]Hong JH, Tsai CS, Chang JT, Wang CC, Lai CH, Lee SP, Tseng CJ, Chang TC, Tang SG: The prognostic significance of pre- and posttreatment SCC levels in patients with squamous cell carcinoma of the cervix treated by radiotherapy. Int J Radiat Oncol Biol Phys 1998, 41(4):823-830.
  • [5]Hong JH, Tsai CS, Lai CH, Chang TC, Wang CC, Chou HH, Lee SP, Hsueh S: Recurrent squamous cell carcinoma of cervix after definitive radiotherapy. Int J Radiat Oncol Biol Phys 2004, 60(1):249-257.
  • [6]Arthur D, Kaufman N, Schmidt-Ullrich R, Kavanagh B, Simpson P, Hill M, Ali M: Heuristically derived tumor burden score as a prognostic factor for stage IIIB carcinoma of the cervix. Int J Radiat Oncol Biol Phys 1995, 31(4):743-751.
  • [7]Hsu HC, Leung SW, Huang EY, Wang CJ, Sun LM, Fang FM, Chen HC: Impact of the extent of parametrial involvement in patients with carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 1998, 40(2):405-410.
  • [8]Huang EY, Wang CJ, Lan JH, Chen HC, Fang FM, Hsu HC, Huang YJ, Wang CY, Wang YM: Factors for predicting rectal dose of high-dose-rate intracavitary brachytherapy after pelvic irradiation in patients with cervical cancer: a retrospective study with radiography-based dosimetry. Int J Radiat Oncol Biol Phys 2010, 76(2):490-495.
  • [9]Huang EY, Hsu HC, Sun LM, Chanchien CC, Lin H, Chen HC, Tseng CW, Ou YC, Chang HY, Fang FM, Huang YJ, Wang CY, Lu HM, Tsai CC, Ma YY, Fu HC, Wang YM, Wang CJ: Prognostic value of pretreatment carcinoembryonic antigen after definitive radiotherapy with or without concurrent chemotherapy for squamous cell carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 2011, 81(4):1105-1113.
  • [10]Eifel PJ, Winter K, Morris M, Levenback C, Grigsby PW, Cooper J, Rotman M, Gershenson D, Mutch DG: Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol 2004, 22(5):872-880.
  • [11]Niibe Y, Hayakawa K: Oligometastases and oligo-recurrence: the new era of cancer therapy. Jpn J Clin Oncol 2010, 40(2):107-111.
  • [12]Niibe Y, Kazumoto T, Toita T, Yamazaki H, Higuchi K, Ii N, Suzuki K, Uno T, Tokumaru S, Takayama M, Sekiguchi K, Matsumoto Y, Michimoto K, Oguchi M, Hayakawa K: Frequency and characteristics of isolated para-aortic lymph node recurrence in patients with uterine cervical carcinoma in Japan: a multi-institutional study. Gynecol Oncol 2006, 103(2):435-438.
  • [13]Yeung AR, Amdur RJ, Morris CG, Morgan LS, Mendenhall WM: Long-term outcome after radiotherapy for FIGO stage IIIB and IVA carcinoma of the cervix. Int J Radiat Oncol Biol Phys 2007, 67(5):1445-1450.
  • [14]Sakurai H, Mitsuhashi N, Takahashi M, Akimoto T, Muramatsu H, Ishikawa H, Imai R, Yamakawa M, Hasegawa M, Niibe H: Analysis of recurrence of squamous cell carcinoma of the uterine cervix after definitive radiation therapy alone: patterns of recurrence, latent periods, and prognosis. Int J Radiat Oncol Biol Phys 2001, 50(5):1136-1144.
  • [15]Leblanc E, Gauthier H, Querleu D, Ferron G, Zerdoud S, Morice P, Uzan C, Lumbroso S, Lecuru F, Bats AS, Ghazzar N, Bannier M, Houvenaeghel G, Brenot-Rossi I, Narducci F: Accuracy of 18-fluoro-2-deoxy-D-glucose positron emission tomography in the pretherapeutic detection of occult para-aortic node involvement in patients with a locally advanced cervical carcinoma. Ann Surg Oncol 2011, 18(8):2302-2309.
  • [16]Uzan C, Souadka A, Gouy S, Debaere T, Duclos J, Lumbroso J, Haie-Meder C, Morice P: Analysis of morbidity and clinical implications of laparoscopic para-aortic lymphadenectomy in a continuous series of 98 patients with advanced-stage cervical cancer and negative PET-CT imaging in the para-aortic area. Oncologist 2011, 16(7):1021-1027.
  • [17]Heller PB, Maletano JH, Bundy BN, Barnhill DR, Okagaki T: Clinical-pathologic study of stage IIB, III, and IVA carcinoma of the cervix: extended diagnostic evaluation for paraaortic node metastasis--a Gynecologic Oncology Group study. Gynecol Oncol 1990, 38(3):425-430.
  • [18]Ramirez PT, Jhingran A, Macapinlac HA, Euscher ED, Munsell MF, Coleman RL, Soliman PT, Schmeler KM, Frumovitz M, Ramondetta LM: Laparoscopic extraperitoneal para-aortic lymphadenectomy in locally advanced cervical cancer: a prospective correlation of surgical findings with positron emission tomography/computed tomography findings. Cancer 2011, 117(9):1928-1934.
  • [19]Beriwal S, Gan GN, Heron DE, Selvaraj RN, Kim H, Lalonde R, Kelley JL, Edwards RP: Early clinical outcome with concurrent chemotherapy and extended-field, intensity-modulated radiotherapy for cervical cancer. Int J Radiat Oncol Biol Phys 2007, 68(1):166-171.
  • [20]Singh AK, Grigsby PW, Rader JS, Mutch DG, Powell MA: Cervix carcinoma, concurrent chemoradiotherapy, and salvage of isolated paraaortic lymph node recurrence. Int J Radiat Oncol Biol Phys 2005, 61(2):450-455.
  • [21]Chou HH, Wang CC, Lai CH, Hong JH, Ng KK, Chang TC, Tseng CJ, Tsai CS, Chang JT: Isolated paraaortic lymph node recurrence after definitive irradiation for cervical carcinoma. Int J Radiat Oncol Biol Phys 2001, 51(2):442-488.
  • [22]Arrieta O, Saavedra-Perez D, Kuri R, Aviles-Salas A, Martinez L, Mendoza-Posada D, Castillo P, Astorga A, Guzman E, De la Garza J: Brain metastasis development and poor survival associated with carcinoembryonic antigen (CEA) level in advanced non-small cell lung cancer: a prospective analysis. BMC Cancer 2009, 9:119. BioMed Central Full Text
  • [23]Ikeda Y, Mori M, Kajiyama K, Kamakura T, Maehara Y, Haraguchi Y, Sugimachi K: Indicative value of carcinoembryonic antigen (CEA) for liver recurrence following curative resection of stage II and III gastric cancer. Hepatogastroenterology 1996, 43(11):1281-1287.
  • [24]Moreno García V, Cejas P, Blanco Codesido M, Feliu Batlle J, de Castro Carpeño J, Belda-Iniesta C, Barriuso J, Sánchez JJ, Larrauri J, González-Barón M, Casado E: Prognostic value of carcinoembryonic antigen level in rectal cancer treated with neoadjuvant chemoradiotherapy. Int J Colorectal Dis 2009, 24(7):741-748.
  • [25]Park JY, Lee KH: Carcinoembryonic antigen and patterns of recurrence after curative resection of the colorectal cancer. Hepatogastroenterology 2007, 54(79):1966-1969.
  • [26]Hostetter RB, Augustus LB, Mankarious R, Chi KF, Fan D, Toth C, Thomas P, Jessup JM: Carcinoembryonic antigen as a selective enhancer of colorectal cancer metastasis. J Natl Cancer Inst 1990, 82(5):380-385.
  • [27]Niibe Y, Kenjo M, Kazumoto T, Michimoto K, Takayama M, Yamauchi C, Kataoka M, Suzuki K, Ii N, Uno T, Takanaka T, Higuchi K, Yamazaki H, Tokumaru S, Oguchi M, Hayakawa K, Japanease Isolated Para-Aortic Lymph Node Recurrence of Uterine Cervical Carcinoma Study Group: Multi-institutional study of radiation therapy for isolated para-aortic lymph node recurrence in uterine cervical carcinoma: 84 subjects of a population of more than 5,000. Int J Radiat Oncol Biol Phys 2006, 66(5):1366-1369.
  文献评价指标  
  下载次数:3次 浏览次数:12次